Spectrum’s Delay In Starting Confirmatory Trial Of Poziotinib Troubles US FDA

 
• By Brenda Sandburg
Benefits_risks
FDA panel to weigh the benefits and risks of Spectrum's lung cancer drug poziotinib • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers